{
    "organizations": [],
    "uuid": "888f2fbbe6e2e98fbde903aa0b30b48e10af4f58",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/04/20/globe-newswire-newlink-genetics-to-host-its-first-quarter-2018-financial-results-conference-call-on-may-3-2018.html",
    "ord_in_thread": 0,
    "title": "NewLink Genetics to Host Its First Quarter 2018 Financial Results Conference Call on May 3, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "AMES, Iowa, April 20, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its first quarter 2018 financial results on Thursday, May 3, 2018. The company has scheduled a conference call for 4:30 PM ET the same day to discuss the results.\nNewLink Genetics' senior management team will host the conference call, which will be open to all listeners. There will also be a question and answer session following the prepared remarks.\nAccess to the live call is available by dialing (855) 469-0612 (U.S.) or (484) 756-4268 (international) five minutes prior to the start of the call. The conference call will be webcast live and a link can be accessed through the NewLink Genetics website at https://edge.media-server.com/m6/p/7pbbadk4 . A replay of the call will be available for two weeks from the date of the call and can be accessed by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (international) and using the passcode 6768809.\nAbout NewLink Genetics Corporation\nNewLink Genetics is a late-stage biopharmaceutical company focusing on discovering, developing and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. NewLink Genetics' IDO pathway inhibitors are designed to harness multiple components of the immune system to combat cancer. Indoximod, the companyâ€™s leading IDO inhibitor, is being evaluated in combination with treatment regimens including anti-PD-1/PD-L1 agents, chemotherapy, radiation and cancer vaccines across multiple indications such as melanoma, pancreatic cancer and other malignancies. For more information, visit www.newlinkgenetics.com , and follow us on Twitter @NLNKGenetics .\nInvestor Contact:\nLisa Miller\nDirector of Investor Relations\nNewLink Genetics\n(515) 598-2555\nlmiller@linkp.com\nMedia Contact:\nSharon Correia\nVP, Integrated Communications\nLaVoieHealthScience\n617-374-8800, ext. 105\nscorreia@lavoiehealthscience.com\nSource:NewLink Genetics Corporation",
    "published": "2018-04-20T17:00:00.000+03:00",
    "crawled": "2018-04-20T17:47:47.010+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "ames",
        "iowa",
        "april",
        "globe",
        "newswire",
        "newlink",
        "genetics",
        "corporation",
        "nasdaq",
        "nlnk",
        "today",
        "announced",
        "release",
        "first",
        "quarter",
        "financial",
        "result",
        "thursday",
        "may",
        "company",
        "scheduled",
        "conference",
        "call",
        "pm",
        "et",
        "day",
        "discus",
        "result",
        "newlink",
        "genetics",
        "senior",
        "management",
        "team",
        "host",
        "conference",
        "call",
        "open",
        "listener",
        "also",
        "question",
        "answer",
        "session",
        "following",
        "prepared",
        "remark",
        "access",
        "live",
        "call",
        "available",
        "dialing",
        "international",
        "five",
        "minute",
        "prior",
        "start",
        "call",
        "conference",
        "call",
        "webcast",
        "live",
        "link",
        "accessed",
        "newlink",
        "genetics",
        "website",
        "http",
        "replay",
        "call",
        "available",
        "two",
        "week",
        "date",
        "call",
        "accessed",
        "dialing",
        "international",
        "using",
        "passcode",
        "newlink",
        "genetics",
        "corporation",
        "newlink",
        "genetics",
        "biopharmaceutical",
        "company",
        "focusing",
        "discovering",
        "developing",
        "commercializing",
        "novel",
        "product",
        "candidate",
        "improve",
        "life",
        "patient",
        "cancer",
        "newlink",
        "genetics",
        "ido",
        "pathway",
        "inhibitor",
        "designed",
        "harness",
        "multiple",
        "component",
        "immune",
        "system",
        "combat",
        "cancer",
        "indoximod",
        "company",
        "leading",
        "ido",
        "inhibitor",
        "evaluated",
        "combination",
        "treatment",
        "regimen",
        "including",
        "agent",
        "chemotherapy",
        "radiation",
        "cancer",
        "vaccine",
        "across",
        "multiple",
        "indication",
        "melanoma",
        "pancreatic",
        "cancer",
        "malignancy",
        "information",
        "visit",
        "follow",
        "u",
        "twitter",
        "nlnkgenetics",
        "investor",
        "contact",
        "lisa",
        "miller",
        "director",
        "investor",
        "relation",
        "newlink",
        "genetics",
        "lmiller",
        "medium",
        "contact",
        "sharon",
        "correia",
        "vp",
        "integrated",
        "communication",
        "lavoiehealthscience",
        "ext",
        "scorreia",
        "source",
        "newlink",
        "genetics",
        "corporation"
    ]
}